molybdenum has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Li, Y; Shi, H; Tang, Y; Wang, S; Xu, Z; Yuan, C; Zhang, J | 1 |
| Lee, H; Murugan, C; Park, S | 1 |
| Li, Z; Liang, Z; Ma, Q; Shi, J; Wang, P; Zhao, H; Zhong, W | 1 |
| Alsayed, A; He, C; Karginova, O; Lee, SS; Olopade, OI; Raoul, A; Weekley, CM; Wu, T | 1 |
| Garber, K | 1 |
| Aljom, E; Chan, N; Chuang, E; Cigler, T; Donovan, D; Fischbach, C; Fitzpatrick, V; Guillaume-Abraham, J; Kornhauser, N; Lane, ME; Lee, SB; Mittal, V; Moore, A; Nackos, E; Schneider, S; Seo, BR; Vahdat, L; Vallee Cobham, M; Ward, MM; Warren, JD; Wiener, A; Willis, A; Zelkowitz, R | 1 |
1 trial(s) available for molybdenum and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Topics: Adenocarcinoma; Amino Acid Oxidoreductases; Animals; Breast Neoplasms; Cell Line, Tumor; Ceruloplasmin; Chelating Agents; Copper; Disease Progression; Disease-Free Survival; Endothelial Progenitor Cells; Female; Follow-Up Studies; Humans; Lung Neoplasms; Mice, SCID; Molybdenum; Neoplasm Proteins; Neovascularization, Pathologic; Neutropenia; Risk; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
5 other study(ies) available for molybdenum and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer.
Topics: Animals; B7-H1 Antigen; Cell Line, Tumor; Glutamine; Humans; Immune Checkpoint Inhibitors; Ligands; Mice; Molybdenum; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
Tumor-targeted molybdenum disulfide@barium titanate core-shell nanomedicine for dual photothermal and chemotherapy of triple-negative breast cancer cells.
Topics: Barium; Humans; Molybdenum; Nanomedicine; Phototherapy; Triple Negative Breast Neoplasms | 2023 |
ECL resonance energy transfer-regulated "off-on" mode biosensor for the detection of miRNA-150-5p in triple negative breast cancer.
Topics: Biosensing Techniques; Energy Transfer; Humans; MicroRNAs; Molybdenum; Triple Negative Breast Neoplasms | 2023 |
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis.
Topics: Animals; Apoptosis; Benzothiazoles; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Copper; Copper Transport Proteins; Copper-Transporting ATPases; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Chaperones; Molybdenum; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Small Molecule Libraries; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
BIOMEDICINE. Targeting copper to treat breast cancer.
Topics: Angiogenesis Inhibitors; Chelating Agents; Clinical Trials, Phase III as Topic; Copper; Female; Humans; Mammography; Molecular Targeted Therapy; Molybdenum; Triple Negative Breast Neoplasms | 2015 |